TODENTJ-25-03-2019_TODENTJ-12-455
1553507403
Bentham Open
doi@benthamopen.net
Bentham Open
The Open Dentistry Journal
TODENTJ
1874-2106
6
20
2018
12
1
Perspectives of Immune Suppression in the Tumor Microenvironment Promoting Oral Malignancy
Nobuo
Kondoh
Masako
Mizuno-Kamiya
Eiji
Takayama
Harumi
Kawati
Naoki
Umemura
Yutaka
Yamazaki
Kenji
Mitsudo
Iwai
Tohnai
Introduction:
In order to survive, cancers control immune systems and evade immune detection using mediators consisting of immune checkpoint molecules and cellular systems associated with immune suppression.
Methodology:
During the development of cancer and chronic infections, the immune checkpoints and cellular components including regulatory T cells, myeloid derived suppressor cells and cancer associated fibroblasts are often enhanced as a mechanism of immune subversion and have therefore become very important therapeutic targets.
Conclusion:
In this review, we will discuss the complexity of immune-suppressive mechanisms in the tumor milieu of cancers, including oral malignancy.
6
20
2018
455
465
TODENTJ-12-455
1
10.2174/crossmark_policy
opendentistryjournal.com
benthamopen.com
true
Peer Reviewed
Single blind
Checked with iThenticate
2018-04-13
2018-05-15
2018-05-29
2018-6-20
https://creativecommons.org/licenses/by/4.0/legalcode
10.2174/1874210601812010455
1553507403
https://opendentistryjournal.com/VOLUME/12/PAGE/455/
-
https://opendentistryjournal.com/contents/volumes/V12/TODENTJ-12-455/TODENTJ-12-455.pdf
-
https://opendentistryjournal.com/contents/volumes/V12/TODENTJ-12-455/TODENTJ-12-455.pdf
-
https://opendentistryjournal.com/contents/volumes/V12/TODENTJ-12-455/TODENTJ-12-455.pdf
-
https://opendentistryjournal.com/contents/volumes/V12/TODENTJ-12-455/TODENTJ-12-455.pdf
-
https://opendentistryjournal.com/contents/volumes/V12/TODENTJ-12-455/TODENTJ-12-455.pdf
-
https://opendentistryjournal.com/contents/volumes/V12/TODENTJ-12-455/TODENTJ-12-455.pdf
-
https://opendentistryjournal.com/contents/volumes/V12/TODENTJ-12-455/TODENTJ-12-455.pdf
-
https://opendentistryjournal.com/contents/volumes/V12/TODENTJ-12-455/TODENTJ-12-455.xml
Cell
Hanahan D.
144
646
2011
10.1016/j.cell.2011.02.013
Hanahan D, Weinberg RA.
Hallmarks of cancer: the next generation.
Cell
2011;
144
(5)
: 646-74.
Cancer Immunol. Immunother.
Takahashi H.
64
1407
2015
10.1007/s00262-015-1742-0
Takahashi H, Sakakura K, Kawabata-Iwakawa R, et al.
Immunosuppressive activity of cancer-associated fibroblasts in head and neck squamous cell carcinoma.
Cancer Immunol Immunother
2015;
64
(11)
: 1407-17.
Arch. Oral Biol.
Arantes D.A.
61
28
2016
10.1016/j.archoralbio.2015.10.013
Arantes DA, Costa NL, Mendonça EF, Silva TA, Batista AC.
Overexpression of immunosuppressive cytokines is associated with poorer clinical stage of oral squamous cell carcinoma.
Arch Oral Biol
2016;
61
: 28-35.
Exp. Cell Res.
Dudás J.
317
2222
2011
10.1016/j.yexcr.2011.05.023
Dudás J, Fullár A, Bitsche M, et al.
Tumor-produced, active interleukin-1β regulates gene expression in carcinoma-associated fibroblasts.
Exp Cell Res
2011;
317
(15)
: 2222-9.
Neoplasia
Bae J.Y.
16
928
2014
10.1016/j.neo.2014.09.003
Bae JY, Kim EK, Yang DH, et al.
Reciprocal interaction between carcinoma-associated fibroblasts and squamous carcinoma cells through interleukin-1α induces cancer progression.
Neoplasia
2014;
16
(11)
: 928-38.
Adv. Cancer Res.
Parker K.H.
128
95
2015
10.1016/bs.acr.2015.04.002
Parker KH, Beury DW, Ostrand-Rosenberg S.
Myeloid-Derived Suppressor Cells: Critical cells driving immune suppression in the tumor microenvironment.
Adv Cancer Res
2015;
128
: 95-139.
Semin. Cell Dev. Biol.
Franco O.E.
21
33
2010
10.1016/j.semcdb.2009.10.010
Franco OE, Shaw AK, Strand DW, Hayward SW.
Cancer associated fibroblasts in cancer pathogenesis.
Semin Cell Dev Biol
2010;
21
(1)
: 33-9.
Cytokine Growth Factor Rev.
De Rosa V.
35
15
2017
10.1016/j.cytogfr.2017.04.001
De Rosa V, Di Rella F, Di Giacomo A, Matarese G.
Regulatory T cells as suppressors of anti-tumor immunity: Role of metabolism.
Cytokine Growth Factor Rev
2017;
35
: 15-25.
Eur. J. Immunol.
Dyck L.
47
765
2017
10.1002/eji.201646875
Dyck L, Mills KHG.
Immune checkpoints and their inhibition in cancer and infectious diseases.
Eur J Immunol
2017;
47
(5)
: 765-79.
Trends Immunol.
Pauken K.E.
36
265
2015
10.1016/j.it.2015.02.008
Pauken KE, Wherry EJ.
Overcoming T cell exhaustion in infection and cancer.
Trends Immunol
2015;
36
(4)
: 265-76.
Oncogene
Butt A.Q.
33
4623
2014
10.1038/onc.2013.432
Butt AQ, Mills KH.
Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines.
Oncogene
2014;
33
(38)
: 4623-31.
Trends Immunol.
Ceeraz S.
34
556
2013
10.1016/j.it.2013.07.003
Ceeraz S, Nowak EC, Noelle RJ.
B7 family checkpoint regulators in immune regulation and disease.
Trends Immunol
2013;
34
(11)
: 556-63.
J. Exp. Med.
Linsley P.S.
174
561
1991
10.1084/jem.174.3.561
Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA.
CTLA-4 is a second receptor for the B cell activation antigen B7.
J Exp Med
1991;
174
(3)
: 561-9.
J. Exp. Med.
van der Merwe P.A.
185
393
1997
10.1084/jem.185.3.393
van der Merwe PA, Bodian DL, Daenke S, Linsley P, Davis SJ.
CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics.
J Exp Med
1997;
185
(3)
: 393-403.
Oncotarget
Huang P.Y.
7
13060
2016
10.18632/oncotarget.7421
Huang PY, Guo SS, Zhang Y, et al.
Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma.
Oncotarget
2016;
7
(11)
: 13060-8.
Curr. Cancer Drug Targets
Mao H.
10
728
2010
10.2174/156800910793605811
Mao H, Zhang L, Yang Y, et al.
New insights of CTLA-4 into its biological function in breast cancer.
Curr Cancer Drug Targets
2010;
10
(7)
: 728-36.
Cancer Res.
Duraiswamy J.
73
3591
2013
10.1158/0008-5472.CAN-12-4100
Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G.
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
Cancer Res
2013;
73
(12)
: 3591-603.
J. Clin. Oncol.
Hodi F.S.
31
3182
2013
10.1200/JCO.2012.47.7836
Hodi FS, Corless CL, Giobbie-Hurder A, et al.
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
J Clin Oncol
2013;
31
(26)
: 3182-90.
Clin. Epigenetics
Basu B.
9
13
2017
10.1186/s13148-017-0314-x
Basu B, Chakraborty J, Chandra A, et al.
Genome-wide DNA methylation profile identified a unique set of differentially methylated immune genes in oral squamous cell carcinoma patients in India.
Clin Epigenetics
2017;
9
: 13.
J. Oral Pathol. Med.
Wong Y.K.
35
51
2006
10.1111/j.1600-0714.2005.00377.x
Wong YK, Chang KW, Cheng CY, Liu CJ.
Association of CTLA-4 gene polymorphism with oral squamous cell carcinoma.
J Oral Pathol Med
2006;
35
(1)
: 51-4.
EMBO J.
Ishida Y.
11
3887
1992
Ishida Y, Agata Y, Shibahara K, Honjo T.
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
EMBO J
1992;
11
(11)
: 3887-95.
Am. J. Clin. Oncol.
Buchbinder E.I.
39
98
2016
10.1097/COC.0000000000000239
Buchbinder EI, Desai A.
CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition.
Am J Clin Oncol
2016;
39
(1)
: 98-106.
Blood
Ahmadzadeh M.
114
1537
2009
10.1182/blood-2008-12-195792
Ahmadzadeh M, Johnson LA, Heemskerk B, et al.
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.
Blood
2009;
114
(8)
: 1537-44.
Proc. Natl. Acad. Sci. USA
Matsuzaki J.
107
7875
2010
10.1073/pnas.1003345107
Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, et al.
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.
Proc Natl Acad Sci USA
2010;
107
(17)
: 7875-80.
Oncotarget
Oliveira-Costa J.P.
6
20902
2015
10.18632/oncotarget.3939
Oliveira-Costa JP, de Carvalho AF, da Silveira GG, et al.
Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells.
Oncotarget
2015;
6
(25)
: 20902-20.
Int. J. Oncol.
Hirai M.
50
41
2017
10.3892/ijo.2016.3785
Hirai M, Kitahara H, Kobayashi Y, et al.
Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment.
Int J Oncol
2017;
50
(1)
: 41-8.
Cancer Immunol. Immunother.
Malaspina T.S.
60
965
2011
10.1007/s00262-011-1007-5
Malaspina TS, Gasparoto TH, Costa MR, et al.
Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma.
Cancer Immunol Immunother
2011;
60
(7)
: 965-74.
J. Exp. Med.
Francisco L.M.
206
3015
2009
10.1084/jem.20090847
Francisco LM, Salinas VH, Brown KE, et al.
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells.
J Exp Med
2009;
206
(13)
: 3015-29.
Cancer Immunol. Immunother.
Dyck L.
65
1491
2016
10.1007/s00262-016-1906-6
Dyck L, Wilk MM, Raverdeau M, Misiak A, Boon L, Mills KH.
Anti-PD-1 inhibits Foxp3+ Treg cell conversion and unleashes intratumoural effector T cells thereby enhancing the efficacy of a cancer vaccine in a mouse model.
Cancer Immunol Immunother
2016;
65
(12)
: 1491-8.
Proc. Natl. Acad. Sci. USA
Curran M.A.
107
4275
2010
10.1073/pnas.0915174107
Curran MA, Montalvo W, Yagita H, Allison JP.
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.
Proc Natl Acad Sci USA
2010;
107
(9)
: 4275-80.
J. Clin. Oncol.
van Rooij N.
31
e439
2013
10.1200/JCO.2012.47.7521
van Rooij N, van Buuren MM, Philips D, et al.
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.
J Clin Oncol
2013;
31
(32)
: e439-42.
N. Engl. J. Med.
Snyder A.
371
2189
2014
10.1056/NEJMoa1406498
Snyder A, Makarov V, Merghoub T, et al.
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
N Engl J Med
2014;
371
(23)
: 2189-99.
Science
Rizvi N.A.
348
124
2015
10.1126/science.aaa1348
Rizvi NA, Hellmann MD, Snyder A, et al.
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Science
2015;
348
(6230)
: 124-8.
N. Engl. J. Med.
Ferris R.L.
375
1856
2016
10.1056/NEJMoa1602252
Ferris RL, Blumenschein G Jr, Fayette J, et al.
Nivolumab for recurrent squamous-cell carcinoma of the head and neck.
N Engl J Med
2016;
375
(19)
: 1856-67.
Nat. Rev. Immunol.
Sharpe A.H.
2
116
2002
10.1038/nri727
Sharpe AH, Freeman GJ.
The B7-CD28 superfamily.
Nat Rev Immunol
2002;
2
(2)
: 116-26.
J. Clin. Invest.
Sim G.C.
124
99
2014
10.1172/JCI46266
Sim GC, Martin-Orozco N, Jin L, et al.
IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients.
J Clin Invest
2014;
124
(1)
: 99-110.
Clin. Cancer Res.
Tamura H.
11
5708
2005
10.1158/1078-0432.CCR-04-2672
Tamura H, Dan K, Tamada K, et al.
Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia.
Clin Cancer Res
2005;
11
(16)
: 5708-17.
Oral Oncol.
Kämmerer P.W.
46
543
2010
10.1016/j.oraloncology.2010.03.025
Kämmerer PW, Toyoshima T, Schöder F, et al.
Association of T-cell regulatory gene polymorphisms with oral squamous cell carcinoma.
Oral Oncol
2010;
46
(7)
: 543-8.
Expert Opin. Ther. Targets
Amatore F.
22
343
2018
10.1080/14728222.2018.1444753
Amatore F, Gorvel L, Olive D.
Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy.
Expert Opin Ther Targets
2018;
22
(4)
: 343-51.
Oncol. Lett.
Zhang S.S.
10
1063
2015
10.3892/ol.2015.3274
Zhang SS, Tang J, Yu SY, et al.
Expression levels of B7-H3 and TLT-2 in human oral squamous cell carcinoma.
Oncol Lett
2015;
10
(2)
: 1063-8.
Nat. Immunol.
Chapoval A.I.
2
269
2001
10.1038/85339
Chapoval AI, Ni J, Lau JS, et al.
B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production.
Nat Immunol
2001;
2
(3)
: 269-74.
Nat. Immunol.
Suh W.K.
4
899
2003
10.1038/ni967
Suh WK, Gajewska BU, Okada H, et al.
The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses.
Nat Immunol
2003;
4
(9)
: 899-906.
Eur. J. Immunol.
Wang L.
35
428
2005
10.1002/eji.200425518
Wang L, Fraser CC, Kikly K, et al.
B7-H3 promotes acute and chronic allograft rejection.
Eur J Immunol
2005;
35
(2)
: 428-38.
J. Immunol.
Prasad D.V.
173
2500
2004
10.4049/jimmunol.173.4.2500
Prasad DV, Nguyen T, Li Z, et al.
Murine B7-H3 is a negative regulator of T cells.
J Immunol
2004;
173
(4)
: 2500-6.
Tumour Biol.
Wang L.
37
2961
2016
10.1007/s13277-015-4132-5
Wang L, Cao NN, Wang S, Man HW, Li PF, Shan BE.
Roles of coinhibitory molecules B7-H3 and B7-H4 in esophageal squamous cell carcinoma.
Tumour Biol
2016;
37
(3)
: 2961-71.
Cancer Immunol. Immunother.
Wu L.
65
1035
2016
10.1007/s00262-016-1867-9
Wu L, Deng WW, Yu GT, et al.
B7-H4 expression indicates poor prognosis of oral squamous cell carcinoma.
Cancer Immunol Immunother
2016;
65
(9)
: 1035-45.
Gynecol. Oncol.
Fauci J.M.
127
420
2012
10.1016/j.ygyno.2012.08.017
Fauci JM, Straughn JM Jr, Ferrone S, Buchsbaum DJ.
A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer.
Gynecol Oncol
2012;
127
(2)
: 420-5.
J. Exp. Med.
Kryczek I.
203
871
2006
10.1084/jem.20050930
Kryczek I, Zou L, Rodriguez P, et al.
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma.
J Exp Med
2006;
203
(4)
: 871-81.
Wang L, Rubinstein R, Lines JL, et al.
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med. 2011, 14; 208(3): 577-92.
Cancer Immunol. Immunother.
Wu L.
66
627
2017
10.1007/s00262-017-1968-0
Wu L, Deng WW, Huang CF, et al.
Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma.
Cancer Immunol Immunother
2017;
66
(5)
: 627-36.
Annu. Rev. Immunol.
Sakaguchi S.
22
531
2004
10.1146/annurev.immunol.21.120601.141122
Sakaguchi S.
Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses.
Annu Rev Immunol
2004;
22
: 531-62.
J. Exp. Med.
Setoguchi R.
201
723
2005
10.1084/jem.20041982
Setoguchi R, Hori S, Takahashi T, Sakaguchi S.
Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization.
J Exp Med
2005;
201
(5)
: 723-35.
Trends Mol. Med.
Miyara M.
13
108
2007
10.1016/j.molmed.2007.01.003
Miyara M, Sakaguchi S.
Natural regulatory T cells: mechanisms of suppression.
Trends Mol Med
2007;
13
(3)
: 108-16.
Int. Immunol.
Sakaguchi S.
21
1105
2009
10.1093/intimm/dxp095
Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T.
Regulatory T cells: how do they suppress immune responses?
Int Immunol
2009;
21
(10)
: 1105-11.
J. Immunol.
Lee J.J.
199
467
2017
10.4049/jimmunol.1601815
Lee JJ, Kao KC, Chiu YL, et al.
Enrichment of Human CCR6+ Regulatory T Cells with Superior Suppressive Activity in Oral Cancer.
J Immunol
2017;
199
(2)
: 467-76.
BMC Cancer
Song J.J.
16
530
2016
10.1186/s12885-016-2419-6
Song JJ, Zhao SJ, Fang J, et al.
Foxp3 overexpression in tumor cells predicts poor survival in oral squamous cell carcinoma.
BMC Cancer
2016;
16
: 530.
Acta Histochem.
Hussaini H.M.
119
205
2017
10.1016/j.acthis.2016.12.005
Hussaini HM, Parachuru VPB, Seymour GJ, Rich AM.
Forkhead box-P3+ regulatory T cells and toll-like receptor 2 co-expression in oral squamous cell carcinoma.
Acta Histochem
2017;
119
(3)
: 205-10.
10.1038/nri2506
Gabrilovich DI, Nagaraj S.
Myeloid-derived suppressor cells as regulators of the immune system.
Nat Rev Immunol
2000;
9
(3)
: 162-74.
Annu. Rev. Med.
Condamine T.
66
97
2015
10.1146/annurev-med-051013-052304
Condamine T, Ramachandran I, Youn JI, Gabrilovich DI.
Regulation of tumor metastasis by myeloid-derived suppressor cells.
Annu Rev Med
2015;
66
: 97-110.
J. Clin. Invest.
Marvel D.
125
3356
2015
10.1172/JCI80005
Marvel D, Gabrilovich DI.
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.
J Clin Invest
2015;
125
(9)
: 3356-64.
Cytometry B Clin. Cytom.
Damuzzo V.
88
77
2015
10.1002/cytob.21206
Damuzzo V, Pinton L, Desantis G, et al.
Complexity and challenges in defining myeloid-derived suppressor cells.
Cytometry B Clin Cytom
2015;
88
(2)
: 77-91.
Hum. Immunol.
Boros P.
77
631
2016
10.1016/j.humimm.2016.05.024
Boros P, Ochando J, Zeher M.
Myeloid derived suppressor cells and autoimmunity.
Hum Immunol
2016;
77
(8)
: 631-6.
Nat. Rev. Immunol.
Gabrilovich D.I.
12
253
2012
10.1038/nri3175
Gabrilovich DI, Ostrand-Rosenberg S, Bronte V.
Coordinated regulation of myeloid cells by tumours.
Nat Rev Immunol
2012;
12
(4)
: 253-68.
Nat. Rev. Cancer
Talmadge J.E.
13
739
2013
10.1038/nrc3581
Talmadge JE, Gabrilovich DI.
History of myeloid-derived suppressor cells.
Nat Rev Cancer
2013;
13
(10)
: 739-52.
Tumour Biol.
Yazdani Y.
36
7339
2015
10.1007/s13277-015-4004-z
Yazdani Y, Mohammadnia-Afrouzi M, Yousefi M, et al.
Myeloid-derived suppressor cells in B cell malignancies.
Tumour Biol
2015;
36
(10)
: 7339-53.
Tumour Biol.
Motallebnezhad M.
37
1387
2016
10.1007/s13277-015-4477-9
Motallebnezhad M, Jadidi-Niaragh F, Qamsari ES, Bagheri S, Gharibi T, Yousefi M.
The immunobiology of myeloid-derived suppressor cells in cancer.
Tumour Biol
2016;
37
(2)
: 1387-406.
J. Immunother.
Montero A.J.
35
107
2012
10.1097/CJI.0b013e318242169f
Montero AJ, Diaz-Montero CM, Kyriakopoulos CE, Bronte V, Mandruzzato S.
Myeloid-derived suppressor cells in cancer patients: A clinical perspective.
J Immunother
2012;
35
(2)
: 107-15.
J. Immunol.
Almand B.
166
678
2001
10.4049/jimmunol.166.1.678
Almand B, Clark JI, Nikitina E, et al.
Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer.
J Immunol
2001;
166
(1)
: 678-89.
J. Immunol.
Oyama T.
160
1224
1998
Oyama T, Ran S, Ishida T, et al.
Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells.
J Immunol
1998;
160
(3)
: 1224-32.
J. Immunol.
Ostrand-Rosenberg S.
182
4499
2009
10.4049/jimmunol.0802740
Ostrand-Rosenberg S, Sinha P.
Myeloid-derived suppressor cells: linking inflammation and cancer.
J Immunol
2009;
182
(8)
: 4499-506.
Cancer Res.
Bunt S.K.
67
10019
2007
10.1158/0008-5472.CAN-07-2354
Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S.
Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression.
Cancer Res
2007;
67
(20)
: 10019-26.
Cancer Res.
Wang L.
70
10112
2010
10.1158/0008-5472.CAN-10-0775
Wang L, Yi T, Zhang W, Pardoll DM, Yu H.
IL-17 enhances tumor development in carcinogen-induced skin cancer.
Cancer Res
2010;
70
(24)
: 10112-20.
Breast Cancer Res. Treat.
Morales J.K.
123
39
2010
10.1007/s10549-009-0622-8
Morales JK, Kmieciak M, Knutson KL, Bear HD, Manjili MH.
GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells.
Breast Cancer Res Treat
2010;
123
(1)
: 39-49.
J. Mol. Med. (Berl.)
Yang F.
94
911
2016
10.1007/s00109-016-1398-z
Yang F, Li Y, Wu T, et al.
TNFα-induced M-MDSCs promote transplant immune tolerance via nitric oxide.
J Mol Med (Berl)
2016;
94
(8)
: 911-20.
J. Leukoc. Biol.
Eruslanov E.
88
839
2010
10.1189/jlb.1209821
Eruslanov E, Daurkin I, Ortiz J, Vieweg J, Kusmartsev S.
Pivotal Advance: Tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE2 catabolism in myeloid cells.
J Leukoc Biol
2010;
88
(5)
: 839-48.
Cancer Res.
Parker K.H.
74
5723
2014
10.1158/0008-5472.CAN-13-2347
Parker KH, Sinha P, Horn LA, et al.
HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells.
Cancer Res
2014;
74
(20)
: 5723-33.
J. Bioenerg. Biomembr.
Pedersen P.L.
39
1
2007
10.1007/s10863-007-9070-5
Pedersen PL.
The cancer cell’s “power plants” as promising therapeutic targets: An overview.
J Bioenerg Biomembr
2007;
39
(1)
: 1-12.
J. Immunol.
Husain Z.
191
1486
2013
10.4049/jimmunol.1202702
Husain Z, Huang Y, Seth P, Sukhatme VP.
Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells.
J Immunol
2013;
191
(3)
: 1486-95.
Cell Metab.
Brand A.
24
657
2016
10.1016/j.cmet.2016.08.011
Brand A, Singer K, Koehl GE, et al.
LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells.
Cell Metab
2016;
24
(5)
: 657-71.
Nat. Immunol.
Wynn T.A.
14
197
2013
10.1038/ni.2539
Wynn TA.
Myeloid-cell differentiation redefined in cancer.
Nat Immunol
2013;
14
(3)
: 197-9.
Clin. Cancer Res.
Stromnes I.M.
20
5157
2014
10.1158/1078-0432.CCR-13-0866
Stromnes IM, Greenberg PD, Hingorani SR.
Molecular pathways: myeloid complicity in cancer.
Clin Cancer Res
2014;
20
(20)
: 5157-70.
Oncol. Lett.
Adachi M.
15
3350
2018
Adachi M, Mizuno-Kamiya M, Takayama E, et al.
Gene expression analyses associated with malignant phenotypes of metastatic sub-clones derived from a mouse oral squamous cell carcinoma Sq-1979 cell line.
Oncol Lett
2018;
15
(3)
: 3350-6.
[DOI: 10.3892/ol.2017.7648].
Oncol. Rep.
Sumi S.
37
2897
2017
10.3892/or.2017.5575
Sumi S, Umemura N, Takayama E, et al.
Metastasized murine oral squamous cell carcinoma cells induce intratumoral polymorphonuclear myeloid derived suppressor cells.
Oncol Rep
2017;
37
(5)
: 2897-904.
Cancer Transl. Med.
Azuma Y.
3
194
2017
10.4103/ctm.ctm_30_17
Azuma Y, Mizuno-Kamiya M, Takayama E, et al.
The producing capabilities of interferon-γ and interleukin-10 in primary and metastasized oral squamous cell carcinoma cells.
Cancer Transl Med
2017;
3
(6)
: 194-9.
[DOI: 10.4103/ctm.ctm_30_17].
J. Immunol.
Peláez B.
166
6608
2001
10.4049/jimmunol.166.11.6608
Peláez B, Campillo JA, López-Asenjo JA, Subiza JL.
Cyclophosphamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxide-dependent mechanism.
J Immunol
2001;
166
(11)
: 6608-15.
OncoImmunology
Wu A.A.
4
e1016700
2015
10.1080/2162402X.2015.1016700
Wu AA, Drake V, Huang HS, Chiu S, Zheng L.
Reprogramming the tumor microenvironment: Tumor-induced immunosuppressive factors paralyze T cells.
OncoImmunology
2015;
4
(7)
: e1016700.
Cell Cycle
Baritaki S.
9
4931
2010
10.4161/cc.9.24.14229
Baritaki S, Huerta-Yepez S, Sahakyan A, et al.
Mechanisms of nitric oxide-mediated inhibition of EMT in cancer: Inhibition of the metastasis-inducer Snail and induction of the metastasis-suppressor RKIP.
Cell Cycle
2010;
9
(24)
: 4931-40.
Cancer Res.
Srivastava M.K.
70
68
2010
10.1158/0008-5472.CAN-09-2587
Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S.
Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine.
Cancer Res
2010;
70
(1)
: 68-77.
J. Immunol.
Hanson E.M.
183
937
2009
10.4049/jimmunol.0804253
Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S.
Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells.
J Immunol
2009;
183
(2)
: 937-44.
Oral Surg. Oral Med. Oral Pathol. Oral Radiol.
Grimm M.
121
301
2016
10.1016/j.oooo.2015.10.024
Grimm M, Feyen O, Coy JF, Hofmann H, Teriete P, Reinert S.
Analysis of circulating CD14+/CD16+ monocyte-derived macrophages (MDMs) in the peripheral blood of patients with oral squamous cell carcinoma.
Oral Surg Oral Med Oral Pathol Oral Radiol
2016;
121
(3)
: 301-6.
Anticancer Res.
Iida M.
34
5729
2014
Iida M, Takayama E, Naganawa K, et al.
Increase of peripheral blood CD57+ T-cells in patients with oral squamous cell carcinoma.
Anticancer Res
2014;
34
(10)
: 5729-34.
Hum. Immunol.
Gaur P.
75
330
2014
10.1016/j.humimm.2014.01.011
Gaur P, Singh AK, Shukla NK, Das SN.
Inter-relation of Th1, Th2, Th17 and Treg cytokines in oral cancer patients and their clinical significance.
Hum Immunol
2014;
75
(4)
: 330-7.
Int. J. Oncol.
Hirai M.
50
41
2017
10.3892/ijo.2016.3785
Hirai M, Kitahara H, Kobayashi Y, et al.
Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment.
Int J Oncol
2017;
50
(1)
: 41-8.
Oncotarget
Takahashi H.
8
8633
2017
10.18632/oncotarget.14374
Takahashi H, Sakakura K, Kudo T, et al.
Cancer-associated fibroblasts promote an immunosuppressive microenvironment through the induction and accumulation of protumoral macrophages.
Oncotarget
2017;
8
(5)
: 8633-47.
J. Oral Pathol. Med.
Fujii N.
41
444
2012
10.1111/j.1600-0714.2012.01127.x
Fujii N, Shomori K, Shiomi T, et al.
Cancer-associated fibroblasts and CD163-positive macrophages in oral squamous cell carcinoma: their clinicopathological and prognostic significance.
J Oral Pathol Med
2012;
41
(6)
: 444-51.
Cancer Res.
Mace T.A.
73
3007
2013
10.1158/0008-5472.CAN-12-4601
Mace TA, Ameen Z, Collins A, et al.
Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner.
Cancer Res
2013;
73
(10)
: 3007-18.
Cancer Transl. Med.
Inagaki T.
4
9
2018
10.4103/ctm.ctm_34_17
Inagaki T, Mizunno-Kamiya M, Takayama E, et al.
Suppressive effect of mesenchymal stromal cells on interf eron-γ-producing capability of spleen cells was specifically enhanced via humoral mediator(s) from mouse oral squamous cell carcinoma Sq-1979 cells in vitro.
Cancer Transl Med
2018;
4
(1)
: 9-16.
[DOI: 10.4103/ctm.ctm_34_17].
J. Oral Pathol. Med.
Warnakulasuriya S.
36
575
2007
10.1111/j.1600-0714.2007.00582.x
Warnakulasuriya S, Johnson NW, van der Waal I.
Nomenclature and classification of potentially malignant disorders of the oral mucosa.
J Oral Pathol Med
2007;
36
(10)
: 575-80.
Cochrane Database Syst. Rev.
Walsh T.
21
CD010173
2013
Walsh T, Liu JL, Brocklehurst P, et al.
Clinical assessment to screen for the detection of oral cavity cancer and potentially malignant disorders in apparently healthy adults.
Cochrane Database Syst Rev
2013;
21
(11)
: CD010173.
J. Oral Pathol. Med.
Jin X.
42
355
2013
10.1111/jop.12004
Jin X, Lu S, Xing X, et al.
Thalidomide: features and potential significance in oral precancerous conditions and oral cancer.
J Oral Pathol Med
2013;
42
(5)
: 355-62.
Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.
Wu Y.
110
188
2010
10.1016/j.tripleo.2010.03.034
Wu Y, Zhou G, Zeng H, Xiong CR, Lin M, Zhou HM.
A randomized double-blind, positive-control trial of topical thalidomide in erosive oral lichen planus.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod
2010;
110
(2)
: 188-95.
J. Dent. (Tehran)
Kia S.J.
12
789
2015
Kia SJ, Shirazian S, Mansourian A, Khodadadi Fard L, Ashnagar S.
Comparative efficacy of topical curcumin and triamcinolone for oral lichen planus: A randomized, controlled clinical trial.
J Dent (Tehran)
2015;
12
(11)
: 789-96.
J. Oral Sci.
Thongprasom K.
50
377
2008
10.2334/josnusd.50.377
Thongprasom K, Dhanuthai K.
Steriods in the treatment of lichen planus: A review.
J Oral Sci
2008;
50
(4)
: 377-85.
Br. J. Dermatol.
Wee J.S.
167
36
2012
10.1111/j.1365-2133.2012.10882.x
Wee JS, Shirlaw PJ, Challacombe SJ, Setterfield JF.
Efficacy of mycophenolate mofetil in severe mucocutaneous lichen planus: A retrospective review of 10 patients.
Br J Dermatol
2012;
167
(1)
: 36-43.
J. Eur. Acad. Dermatol. Venereol.
McCaughey C.
25
1061
2011
10.1111/j.1468-3083.2010.03923.x
McCaughey C, Machan M, Bennett R, Zone JJ, Hull CM.
Pimecrolimus 1% cream for oral erosive lichen planus: A 6-week randomized, double-blind, vehicle-controlled study with a 6-week open-label extension to assess efficacy and safety.
J Eur Acad Dermatol Venereol
2011;
25
(9)
: 1061-7.